EMA reflection paper on Patient Experience Data (PED)

1:1
First published on 29 September, this EMA reflection paper encourages early dialogue with regulators on how patient experience data can strengthen evidence packages in medicines development and marketing authorisation.

This EMA reflection paper promotes the inclusion of patient experience data (PED) in medicine development programmes and marketing authorisation applications, defining PED as data that directly reflect the patient experience without interpretation by clinicians or others. It encourages early engagement with regulators to discuss planned approaches and highlights relevant PED types and sources, including patient‑reported outcomes, patient preference studies, patient‑generated digital data, clinical trial data and real‑world data, with the aim of improving how patient experience is captured and used in regulatory decision‑making.

You might also be interested in

Call text draft setting out rules, eligibility and staged application process for the ERDERA Clinical Trial Call 2026.
June 7 - June 10
The Open Academy x ERDERA accompanies patient advocates by offering rare-disease specific comprehensive training programmes that empower advocates with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners.
ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.